Zum Inhalt springen
Global sound
The Bio Report

The Bio Report

Targeting Residual Inflammation in Cardiovascular Disease

· 42 Min. · Folge 195

Shownotes

Cardiovascular disease remains the world's leading cause of death, yet many patients still face substantial risks even after conventional factors such as LDL cholesterol and blood pressure are controlled. Rezera is developing its experimental therapy ruvonoflast, an NLRP3 inhibitor, to address this residual inflammatory risk. The therapy is designed to suppress chronic, tissue-based inflammation while preserving the immune system's ability to respond to infection. Rezera CEO Geoff McDonough discusses the role of inflammation in heart disease, the company’s phase 3 trial of ruvonoflast in peripheral artery disease, and its next-generation, brain-penetrant NLRP3 inhibitor in development for neuroinflammatory conditions.

Website: thebioreport.podbean.com

Live, letzte Stunde: 8.855 Songs auf 3.484 Sendern in 120 Ländern

Entdecke die Welt über das Radio

Mehr zum Entdecken (7)

Etwas Schönes gehört? Speicher es oder öffne es direkt in Spotify.

★ Künstler der Woche Der schnellste Aufsteiger im Radio diese Woche
Dein Song hier? Ab € 9 pro Woche →
Radio 538 luisteren - Live!Gerade beliebt